Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, today announced a $21 million expansion of its previously announced Series B financing, bringing the Series B round total to $87 million. The company will use the additional funds to further advance its portfolio of programs targeting the gut-brain axis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,